These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 10523002)
1. A possible role of immunoglobulin E in patients with hyperthyroid Graves' disease. Sato A; Takemura Y; Yamada T; Ohtsuka H; Sakai H; Miyahara Y; Aizawa T; Terao A; Onuma S; Junen K; Kanamori A; Nakamura Y; Tejima E; Ito Y; Kamijo K J Clin Endocrinol Metab; 1999 Oct; 84(10):3602-5. PubMed ID: 10523002 [TBL] [Abstract][Full Text] [Related]
2. An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease. Yamada T; Sato A; Komiya I; Nishimori T; Ito Y; Terao A; Eto S; Tanaka Y J Clin Endocrinol Metab; 2000 Aug; 85(8):2775-8. PubMed ID: 10946880 [TBL] [Abstract][Full Text] [Related]
3. [An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease]. Sato A; Yamada T Nihon Rinsho; 1999 Aug; 57(8):1904-9. PubMed ID: 10483274 [TBL] [Abstract][Full Text] [Related]
4. Effect of methimazole treatment for 2 years on circulating IL-4, IgE, TBII, and TSAb in patients with hyperthyroid Graves' disease. Yamada T; Komiya I; Miyahara Y; Komatsu M; Shima I; Inazawa T; Aizawa T Endocr J; 2006 Dec; 53(6):783-8. PubMed ID: 16983180 [TBL] [Abstract][Full Text] [Related]
5. An elevation of stem cell factor in patients with hyperthyroid Graves' disease. Yamada T; Sato A; Aizawa T; Ootsuka H; Miyahara Y; Sakai H; Terao A; Onuma S; Ito Y; Kanamori A; Nakamura Y; Tejima E Thyroid; 1998 Jun; 8(6):499-504. PubMed ID: 9669287 [TBL] [Abstract][Full Text] [Related]
6. Remission and recurrence of hyperthyroid Graves' disease during and after methimazole treatment when assessed by IgE and interleukin 13. Komiya I; Yamada T; Sato A; Kouki T; Nishimori T; Takasu N J Clin Endocrinol Metab; 2001 Aug; 86(8):3540-4. PubMed ID: 11502776 [TBL] [Abstract][Full Text] [Related]
7. Significance of thyroid blood flow as a predictor of methimazole sensitivity in untreated hyperthyroid patients with Graves' disease. Nagasaki T; Inaba M; Kumeda Y; Fujiwara-Ueda M; Hiura Y; Nishizawa Y Biomed Pharmacother; 2007 Sep; 61(8):472-6. PubMed ID: 17420111 [TBL] [Abstract][Full Text] [Related]
8. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism. Roti E; Gardini E; Minelli R; Bianconi L; Salvi M; Gavaruzzi G; Braverman LE J Clin Endocrinol Metab; 1993 Apr; 76(4):928-32. PubMed ID: 7682562 [TBL] [Abstract][Full Text] [Related]
9. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission. Murakami M; Koizumi Y; Aizawa T; Yamada T; Takahashi Y; Watanabe T; Kamoi K J Clin Endocrinol Metab; 1988 Jan; 66(1):103-8. PubMed ID: 3121661 [TBL] [Abstract][Full Text] [Related]
10. Thyroid hormone modulates insulin-like growth factor-I(IGF-I) and IGF-binding protein-3, without mediation by growth hormone, in patients with autoimmune thyroid diseases. Inukai T; Takanashi K; Takebayashi K; Fujiwara Y; Tayama K; Takemura Y Horm Metab Res; 1999 Oct; 31(10):576-9. PubMed ID: 10596968 [TBL] [Abstract][Full Text] [Related]
11. The iodine perchlorate discharge test before and after one year of methimazole treatment of hyperthyroid Graves' disease. Roti E; Minelli R; Gardini E; Bianconi L; Salvi M; Gavaruzzi G; Ugolotti G; Braverman LE J Clin Endocrinol Metab; 1994 Mar; 78(3):795-9. PubMed ID: 8126159 [TBL] [Abstract][Full Text] [Related]
12. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy. Antonelli A; Fallahi P; Rotondi M; Ferrari SM; Serio M; Miccoli P Br J Surg; 2006 Oct; 93(10):1226-31. PubMed ID: 16838393 [TBL] [Abstract][Full Text] [Related]
14. Effect of thyrotropin-releasing hormone on serum thyroid hormones: a study in the patients with untreated and treated Graves' disease and subacute thyroiditis. Sato A; Yamada T; Aizawa T; Ichikawa K; Komiya I; Takasu N; Takemura Y J Clin Endocrinol Metab; 1995 Jul; 80(7):2173-7. PubMed ID: 7608274 [TBL] [Abstract][Full Text] [Related]
15. Increased levels of serum interleukin-18 in Graves' disease. Miyauchi S; Matsuura B; Onji M Thyroid; 2000 Sep; 10(9):815-9. PubMed ID: 11041460 [TBL] [Abstract][Full Text] [Related]
16. Natural killer cell activity in patients with Graves' disease and Hashimoto's thyroiditis. Wenzel BE; Chow A; Baur R; Schleusener H; Wall JR Thyroid; 1998 Nov; 8(11):1019-22. PubMed ID: 9848716 [TBL] [Abstract][Full Text] [Related]
17. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Vitti P; Rago T; Chiovato L; Pallini S; Santini F; Fiore E; Rocchi R; Martino E; Pinchera A Thyroid; 1997 Jun; 7(3):369-75. PubMed ID: 9226205 [TBL] [Abstract][Full Text] [Related]
18. Sensitive thyroid-stimulating antibody assay with high concentrations of polyethylene glycol for the diagnosis of Graves' disease. Takasu N; Kamijo K; Sato Y; Yoshimura H; Nagata A; Ochi Y Clin Exp Pharmacol Physiol; 2004; 31(5-6):314-9. PubMed ID: 15191404 [TBL] [Abstract][Full Text] [Related]
19. Acute effects of corticosteroids on thyroid activity in Graves' disease. Williams DE; Chopra IJ; Orgiazzi J; Solomon DH J Clin Endocrinol Metab; 1975 Aug; 41(2):354-61. PubMed ID: 1174132 [TBL] [Abstract][Full Text] [Related]
20. Hashimoto's thyroiditis following Graves' disease. Umar H; Muallima N; Adam JM; Sanusi H Acta Med Indones; 2010 Jan; 42(1):31-5. PubMed ID: 20305330 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]